Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2801 - Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC)


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research



Tumour Site

Ovarian Cancer


Marcia Hall


Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285


M. Hall1, G. Bertelli2, L. Li3, C. Green4, S. Chan5, C.C. Yeoh6, J. Hasan7, A. Ograbek8, T.J. Perren9

Author affiliations

  • 1 Department Of Medical Oncology, Mount Vernon Cancer Centre, HA6 2RN - Northwood/GB
  • 2 Sussex Cancer Centre, Brighton & Sussex University Hospitals NHS Trust (previous affiliation: Singleton Hospital, Swansea), BN2 5BE - Brighton/GB
  • 3 Department Of Oncology And Radiotherapy, James Cook University Hospital, Middlesbrough/GB
  • 4 Oncology Department, Southampton University NHS Trust, Southampton/GB
  • 5 Department Of Oncology And Radiotherapy, Nottingham University Hospital NHS Trust (City Hospital Campus), Nottingham/GB
  • 6 Oncology Department, Queen Alexandra Hospital Portsmouth, PO6 3LY - Portsmouth/GB
  • 7 Department Of Medical Oncology, The Christie Hospital, M20 4BX - Manchester/GB
  • 8 Medical Affairs, Roche Products Ltd, Welwyn Garden City/GB
  • 9 Leeds Institute Of Cancer And Pathology, St James’s University Hospital, LS9 7TF - Leeds/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2801


The efficacy and safety of front-line BEV with carboplatin and paclitaxel (CP) for aOC were demonstrated in two randomised phase III trials (GOG-0218 and ICON7). OSCAR (NCT01863693; funded by Roche Products Ltd) evaluated front-line BEV-containing therapy in routine oncology practice in 29 UK centres.


Eligible patients received BEV (7.5 or 15 mg/kg q3w, typically for up to 12 months, per UK clinical practice) during and after front-line chemotherapy (physician’s choice) for high-risk stage IIIB–IV ovarian cancer. Co-primary endpoints were progression-free survival (PFS) and safety (NCI CTCAE v4.0). Patients were evaluated according to standard practice/physician’s discretion during BEV treatment, with an end-of-study assessment 12 months after the last BEV dose. We report post hoc subgroup analyses in populations defined by age and comorbidities.


Of 299 patients starting treatment between May 2013 and Mar 2015, 80 were aged ≥70 years, of whom 9 were ≥80 years. Almost all patients (91%) had comorbidities (pre-existing medical condition at BEV initiation), most commonly hypertension/essential hypertension (27%), constipation (22%) or fatigue (22%). Most (93%) received BEV 7.5 mg/kg with CP; 22% had primary debulking surgery, 40% interval debulking surgery and 38% no surgery. Patient characteristics, treatment exposure, PFS and safety are summarised below. In multivariable Cox regression analysis, neither age nor number of comorbidities was prognostic for PFS.


Older patients were more likely to receive single-agent chemotherapy, have ongoing comorbidities and have worse surgical outcome than their younger counterparts. However, median BEV exposure, incidence of grade 3/4 AEs and median PFS were similar in younger and older patients. Grade ≥3 AEs were more common in patients with ≥3 than <3 comorbidities but PFS was similar.

Clinical trial identification


Legal entity responsible for the study

Roche Products Ltd.


Roche Products Ltd.

Editorial Acknowledgement

Medical writing assistance was provided by Jennifer Kelly, MA (Medi-Kelsey Ltd, Ashbourne, UK), funded by Roche Products Ltd.Table: 984P

Characteristic, n (%)Age, yearsNo. of comorbidities
<70 (n = 219)≥70 (n = 80)<3 (n = 109)≥3 (n = 190)
Age, years<65 ≥65160 (73) 59 (27)0 80 (100)68 (62) 41 (38)92 (48) 98 (52)
High riska200 (91)70 (88)99 (91)171 (90)
No microscopic residual disease11 (5)1 (1)6 (6)6 (3)
ECOG PS0 1 2 Missing56 (26) 58 (26) 11 (5) 94 (43)13 (16) 27 (34) 6 (8) 34 (43)35 (32) 33 (30) 5 (5) 36 (33)46 (24) 66 (35) 15 (8) 63 (33)
Pre-existing hypertensionb49 (22)33 (41)13 (12)69 (36)
Pre-existing proteinuriac11 (5)10 (13)4 (4)17 (9)
Pre-existing diabetes13 (6)9 (11)2 (2)20 (11)
Selected chemotherapyCP Carboplatin alone Other214 (98) 2 (1) 3 (1)71 (89) 9 (11) 0104 (95) 3 (3) 2 (2)181 (95) 8 (4) 1 (1)
AE leading to BEV discontinuation21 (10)12 (15)11 (10)22 (12)
Median BEV duration, months (range)10.6 (<1–29.7)10.4 (≤1–41.4)10.9 (<1–29.7)10.3 (<1–41.4)
Grade 3/4 AEs, n (%)118 (54)42 (53)50 (46)110 (58)
Grade 5 AEs, n (%)5 (2)d2 (3)e1 (1)6 (3)
Median PFS, months (95% CI)16.1 (14.5–18.5)14.8 (12.2–16.1)16.5 (14.7–18.0)14.9 (13.4–16.1)

Stage III with ≥1 cm residuum, any stage IV, or no surgery.


Includes essential hypertension.


Includes high protein level in urine.


Gastrointestinal perforation, febrile neutropenia, cardiac arrest, pneumonia, metastases to meninges.


Abdominal pain, pneumonia aspiration. AE=adverse event.


M. Hall: Advisory boards: Roche, Tesaro, Clovis Oncology, AstraZeneca. G. Bertelli: Advisory boards: Roche, Novartis, Genomic Health. J. Hasan: Advisory boards: Roche, AstraZeneca, Tesaro. A. Ograbek: Employee: Roche. T.J. Perren: Advisory boards: Roche, Novartis, Merck Sharp & Dohme Limited; Travel/accommodation: IGEA Medical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.